In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clarins

This article was originally published in The Rose Sheet

Executive Summary

Men's skin care line launching in September is expected to account for 5% of Clarins' sales rather than provide firm with 5% in incremental sales as reported in 1"The Rose Sheet" Aug. 19, 2002, p. 8...

You may also be interested in...



Clarins Men Debut Will Be Supported By Sampling, Trial Kits

Clarins will promote the launch of its first men's skin care line with more than 400,000 samples at launch, VP-Marketing Caroline Pieper-Vogt said

US Regulatory Roundup, June 2020: FDA Talks QSR Redo; ISO Risk Standard Gets Companion Doc; Experts Predict Recalls Surge; And More

News out of the US FDA on the harmonization of its Quality System Regulation with ISO 13485, as well as stories on a new ISO technical report on risk management and a warning from experts about probable recalls because of the COVID-19 pandemic, were of most interest to our readers last month. Here are June’s 10 most popular US regulation and policy stories from Medtech Insight.

‘Agile’ Approach Cuts 12 Months From Ridgeback’s COVID-19 Timeline

The Bayesian adaptive trial design helped slash the Phase I time for Ridgeback’s drug, which could provide a pill-based alternative to Gilead’s remdesivir for COVID-19 patients.

UsernamePublicRestriction

Register

LL1132972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel